Key points are not available for this paper at this time.
The study aimed to assess the clinical significance of serum markers Cancer Antigen 125(CA125) and Human Epididymis Protein 4(HE4) combined with MRI in distinguishing between benign and malignant ovarian tumors. Analyzing 140 patients diagnosed with pelvic masses between April 2020 and April 2023, they were categorized into 77 with malignant ovarian tumors (malignant group) and 63 with benign ovarian tumors (benign group), validated by paraffin section pathology-the gold standard. An additional 60 healthy women formed the healthy control group. Serum CA125 and HE4 levels were compared across the groups, and the diagnostic accuracy of CA125, HE4, MRI imaging, and their amalgamations was evaluated. Significantly higher serum CA125 and HE4 levels were observed in the malignant group compared to both the benign group and the healthy control group (P 0.05). Predicting malignant ovarian tumors preoperatively, the accuracy rates were as follows: CA125 at 72.86%, HE4 at 83.57%, MRI at 87.86%, CA125 + HE4 at 90.71%, and MRI + CA125 + HE4 at 97.14%, as per the pathological diagnosis results. Combined with serum CA125, HE4 and MRI can effectively improve the accuracy of early diagnosis of ovarian malignant tumors and provide better medical management and treatment for patients.
Mao et al. (Thu,) studied this question.